PALI Archives - BioTuesdays

Developments

Palisade Bio in GI-licensing deal with Giliant Pharma

Palisade Bio (NASDAQ:PALI) entered into a licensing agreement with closely-held Giliant Pharma for the exclusive worldwide rights to develop, manufacture and commercialize Giiant’s proprietary targeted prodrug platform...

September 6, 2023

Developments

Palisade Bio flunks Phase 2 study in post-surgical abdominal adhesions

Palisade Bio’s (NASDAQ:PALI) U.S. Phase 2 PROFILE study evaluating LB1148 for reduction in intra-abdominal adhesions in subjects following elective bowel resection did not achieve its primary endpoint. Of the patients...

August 9, 2023

Developments

Palisade Bio completes enrollment in dose optimization study

Palisade Bio (NASDAQ:PALI) completed patient enrollment in its dose optimization study of LB1148, a broad-spectrum serine protease inhibitor that acts to neutralize digestive enzymes, potentially reducing intestinal...

July 5, 2023

Developments

Palisade Bio gets FDA fast track for return of bowel function after GI surgery

The FDA granted fast tract designation to Palisade Bio’s (NASDAQ:PALI) LB1148 for the acceleration of time to return of bowel function following surgery. By inhibiting the activity of digestive proteases, the company...

November 22, 2022

Executive Moves

JD Finley named interim CEO of Palisade Bio

Palisade Bio (NASDAQ:PALI) named JD Finley, CFO, as interim CEO, replacing Thomas Hallam, Ph.D., effective Oct. 10. In a statement, James Neal, chairman of Palisade, said Dr. Hallam was “instrumental in the development...

October 11, 2022

Developments

Palisade Bio doses first patient in Phase 3 post-op return of bowel function trial

Palisade Bio (NASDAQ:PALI) dosed the first patient in its Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery. “With what we believe to be a...

August 17, 2022

Developments

Palisade Bio screens first patient in Phase 3 bowel function trial

Palisade Bio (NASDAQ:PALI) screened the first patient in its Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery. “With the first U.S...

July 27, 2022

Developments

Palisade Bio initiates Phase 3 study for postoperative return of bowel function

Palisade Bio (NASDAQ:PALI) initiated a Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery. The first clinical site in the U.S. is now open...

June 29, 2022

Developments

Palisade Bio receives FDA okay for Phase 3 trial for return of bowel function

Palisade Bio (NASDAQ:PALI) received a “study may proceed” letter from the FDA for a Phase 3 clinical trial to evaluate LB1148 to accelerate the return of bowel function in adult patients undergoing...

March 22, 2022

Feature

Palisade Bio guarding against post-operative disruption of GI function

Palisade Bio (NASDAQ:PALI) is advancing therapies that help patients with acute and chronic GI complications, stemming from post-operative tissue damage, to speed recovery and reduce hospital stays.

February 22, 2022

Tag - PALI

Palisade Bio in GI-licensing deal with Giliant Pharma

Palisade Bio flunks Phase 2 study in post-surgical abdominal adhesions

Palisade Bio completes enrollment in dose optimization study

Palisade Bio gets FDA fast track for return of bowel function after GI surgery

JD Finley named interim CEO of Palisade Bio

Palisade Bio doses first patient in Phase 3 post-op return of bowel function trial

Palisade Bio screens first patient in Phase 3 bowel function trial

Palisade Bio initiates Phase 3 study for postoperative return of bowel function

Palisade Bio receives FDA okay for Phase 3 trial for return of bowel function

Palisade Bio guarding against post-operative disruption of GI function

General

More